Clinical Trial Update: Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating a single treatment with FT1050, an ex-vivo modulated umbilical cord blood unit, across multiple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• FT1050

Snippet

Sponsor: Fate Therapeutics | Conditions: Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease | Phase 1 | Status: COMPLETED